story of the week
Atezolizumab Monotherapy vs Chemotherapy for Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
Lancet Oncol 2023 Dec 12;[EPub Ahead of Print], A Bamias, ID Davis, MD Galsky, JÁ Arranz, E Kikuchi, E Grande, XG Del Muro, SH Park, U De Giorgi, B Alekseev, M Mencinger, K Izumi, FA Schutz, J Puente, JR Li, S Panni, M Gumus, M Özgüroğlu, S Mariathasan, Y Poloz, F Bene-Tchaleu, C Lee, S Bernhard, M De SantisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.